BridgeBio Oncology Therapeutics Inc.
BBOT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $73 | $56 | $0 | $0 |
| G&A Expenses | $8 | $8 | $0 | $0 |
| SG&A Expenses | $8 | $8 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $81 | $65 | $0 | $0 |
| Operating Income | -$81 | -$65 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7 | $0 | $0 | $0 |
| Pre-Tax Income | -$74 | -$65 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$74 | -$65 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS | 0.46 | -0.002 | 0 | -0.002 |
| % Growth | 23,100% | – | 100% | – |
| EPS Diluted | 0.46 | -0.002 | 0 | -0.002 |
| Weighted Avg Shares Out | 17 | 20 | 20 | 20 |
| Weighted Avg Shares Out Dil | 17 | 20 | 20 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$81 | -$65 | -$0 | -$0 |
| % Margin | – | – | – | – |